IKNA
Companies
NASDAQ
Ikena Oncology Inc.
Health Care
$1.37
Price Chart
Overview
About IKNA
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
Market Cap
$84.5M
Volume
153.7K
Avg. Volume
142.9K
P/E Ratio
-1.3294117
Dividend Yield
0.00%
Employees
62.0
Company Information
Risk & Correlation Analysis
Market Correlation
N/A
N/A
Volatility
N/A
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, IKNA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$84.5M
Volume153.7K
P/E Ratio-1.33
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 8, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025